Dear Healthcare Professional Letters
Ceftriaxone Therapy (e.g, Rocephin® or Cefotrix®) May Lead to Incorrect Low Results When Using Accu-Chek Compact Plus and Accu-Chek Mobile Blood Glucose Monitoring Systems
Audiences
Healthcare professional
Product type
Medical devices
5 May 2014
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
Roche Diagnostics Asia Pacific Pte Ltd would like to inform healthcare professionals of the modification to the labelling of the Accu-Chek® Compact Plus and Accu-Chek® Mobile Blood Glucose Monitoring Systems, due to the possibility of erroneously low blood glucose readings in patients undergoing ceftriaxone therapy. Healthcare professionals are requested to advise their patients who are on ceftriaxone therapy not to use the affected systems throughout the duration of the therapy and for 2 full days after the last treatment. Patients are advised to use an alternative system. Please refer to the letter for more details.
Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.
Step 1: Select your profession under ‘For Healthcare Professionals’.
Step 2: Click on ‘Useful links’.
Step 3: Click on ‘MOH Alert’ and log in via Singpass.
Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.